Dermatology joined neurology and oncology as the drivers of the US FDA’s novel drug and biologic approvals in 2022, riding a wave of immunomodulation therapies that parallel the continuing rise of immuno-oncology.
Cancer therapies were, reliably, the biggest group of novel approvals by the FDA’s drug and biologic review centers. While the...








